▶ 調査レポート

世界のカタレプシー治療市場 2028年:麻薬、心理療法、その他

• 英文タイトル:Global Catalepsy Treatment Market Insights, Forecast to 2028

Global Catalepsy Treatment Market Insights, Forecast to 2028「世界のカタレプシー治療市場 2028年:麻薬、心理療法、その他」(市場規模、市場予測)調査レポートです。• レポートコード:QY2207C3470
• 出版社/出版日:QYResearch / 2022年7月11日
• レポート形態:英文、PDF、125ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Multi User¥1,087,800 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界のカタレプシー治療の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にカタレプシー治療の世界市場のxxx%を占める「麻薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「クリニック」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国のカタレプシー治療の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのカタレプシー治療市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのカタレプシー治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

カタレプシー治療のグローバル主要メーカーには、Teva Pharmaceutical Industries、Upsher-Smith Laboratories、Piramal Critical Care、Vintage Labs、Saol Therapeutics、Auxilium Pharmaceuticals、Hikma Pharmaceuticals、Cadila Pharmaceuticals、CASI Pharmaceuticals、Covis Pharma、Sumitomo Dainippon Pharma、Biocon、Merck KGaA、Cadila Pharmaceuticals、Eisai、Cipla、Glenmark Pharmaceuticals Limited、Mankind Pharma、Novo Nordisk A/S、Otsuka America Pharmaceutical、WOCKHARDTなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

カタレプシー治療市場は、種類と用途によって区分されます。世界のカタレプシー治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
麻薬、心理療法、その他

【用途別セグメント】
クリニック、病院、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- カタレプシー治療製品概要
- 種類別市場(麻薬、心理療法、その他)
- 用途別市場(クリニック、病院、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のカタレプシー治療販売量予測2017-2028
- 世界のカタレプシー治療売上予測2017-2028
- カタレプシー治療の地域別販売量
- カタレプシー治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別カタレプシー治療販売量
- 主要メーカー別カタレプシー治療売上
- 主要メーカー別カタレプシー治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(麻薬、心理療法、その他)
- カタレプシー治療の種類別販売量
- カタレプシー治療の種類別売上
- カタレプシー治療の種類別価格
・用途別市場規模(クリニック、病院、その他)
- カタレプシー治療の用途別販売量
- カタレプシー治療の用途別売上
- カタレプシー治療の用途別価格
・北米市場
- 北米のカタレプシー治療市場規模(種類別、用途別)
- 主要国別のカタレプシー治療市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのカタレプシー治療市場規模(種類別、用途別)
- 主要国別のカタレプシー治療市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のカタレプシー治療市場規模(種類別、用途別)
- 主要国別のカタレプシー治療市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のカタレプシー治療市場規模(種類別、用途別)
- 主要国別のカタレプシー治療市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのカタレプシー治療市場規模(種類別、用途別)
- 主要国別のカタレプシー治療市場規模(トルコ、サウジアラビア)
・企業情報
Teva Pharmaceutical Industries、Upsher-Smith Laboratories、Piramal Critical Care、Vintage Labs、Saol Therapeutics、Auxilium Pharmaceuticals、Hikma Pharmaceuticals、Cadila Pharmaceuticals、CASI Pharmaceuticals、Covis Pharma、Sumitomo Dainippon Pharma、Biocon、Merck KGaA、Cadila Pharmaceuticals、Eisai、Cipla、Glenmark Pharmaceuticals Limited、Mankind Pharma、Novo Nordisk A/S、Otsuka America Pharmaceutical、WOCKHARDT
・産業チェーン及び販売チャネル分析
- カタレプシー治療の産業チェーン分析
- カタレプシー治療の原材料
- カタレプシー治療の生産プロセス
- カタレプシー治療の販売及びマーケティング
- カタレプシー治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- カタレプシー治療の産業動向
- カタレプシー治療のマーケットドライバー
- カタレプシー治療の課題
- カタレプシー治療の阻害要因
・主な調査結果

A state of marked loss of voluntary mobility in which the limbs remain in whatever posture they are placed is known as catalepsy. Voluntary motion loss, muscle rigidity, fixed posture, and diminished pain sensitivity are all symptoms of catalepsy. It can be a sign of a variety of diseases, including epilepsy, Parkinson’s disease, substance abuse, catatonia, schizophrenia, and as a side effect of certain types of schizophrenia treatment. The treatment for catalepsy is determined by the underlying cause of the symptom. Antipsychotic medicines and muscle relaxants are two treatments that may be used to help with catalepsy.
Market Analysis and Insights: Global Catalepsy Treatment Market
The global Catalepsy Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Drugs accounting for % of the Catalepsy Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Clinic segment is altered to an % CAGR throughout this forecast period.
China Catalepsy Treatment market size is valued at US$ million in 2021, while the North America and Europe Catalepsy Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Catalepsy Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Catalepsy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Catalepsy Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Catalepsy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Catalepsy Treatment market.
Global Catalepsy Treatment Scope and Market Size
Catalepsy Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Catalepsy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Drugs
Psychotherapy
Others
Segment by Application
Clinic
Hospital
Others
By Company
Teva Pharmaceutical Industries
Upsher-Smith Laboratories
Piramal Critical Care
Vintage Labs
Saol Therapeutics
Auxilium Pharmaceuticals
Hikma Pharmaceuticals
Cadila Pharmaceuticals
CASI Pharmaceuticals
Covis Pharma
Sumitomo Dainippon Pharma
Biocon
Merck KGaA
Cadila Pharmaceuticals
Eisai
Cipla
Glenmark Pharmaceuticals Limited
Mankind Pharma
Novo Nordisk A/S
Otsuka America Pharmaceutical
WOCKHARDT
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Catalepsy Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Drugs
1.2.3 Psychotherapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Catalepsy Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Catalepsy Treatment Market Perspective (2017-2028)
2.2 Catalepsy Treatment Growth Trends by Region
2.2.1 Catalepsy Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Catalepsy Treatment Historic Market Size by Region (2017-2022)
2.2.3 Catalepsy Treatment Forecasted Market Size by Region (2023-2028)
2.3 Catalepsy Treatment Market Dynamics
2.3.1 Catalepsy Treatment Industry Trends
2.3.2 Catalepsy Treatment Market Drivers
2.3.3 Catalepsy Treatment Market Challenges
2.3.4 Catalepsy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Catalepsy Treatment Players by Revenue
3.1.1 Global Top Catalepsy Treatment Players by Revenue (2017-2022)
3.1.2 Global Catalepsy Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Catalepsy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Catalepsy Treatment Revenue
3.4 Global Catalepsy Treatment Market Concentration Ratio
3.4.1 Global Catalepsy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Catalepsy Treatment Revenue in 2021
3.5 Catalepsy Treatment Key Players Head office and Area Served
3.6 Key Players Catalepsy Treatment Product Solution and Service
3.7 Date of Enter into Catalepsy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Catalepsy Treatment Breakdown Data by Type
4.1 Global Catalepsy Treatment Historic Market Size by Type (2017-2022)
4.2 Global Catalepsy Treatment Forecasted Market Size by Type (2023-2028)
5 Catalepsy Treatment Breakdown Data by Application
5.1 Global Catalepsy Treatment Historic Market Size by Application (2017-2022)
5.2 Global Catalepsy Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Catalepsy Treatment Market Size (2017-2028)
6.2 North America Catalepsy Treatment Market Size by Type
6.2.1 North America Catalepsy Treatment Market Size by Type (2017-2022)
6.2.2 North America Catalepsy Treatment Market Size by Type (2023-2028)
6.2.3 North America Catalepsy Treatment Market Share by Type (2017-2028)
6.3 North America Catalepsy Treatment Market Size by Application
6.3.1 North America Catalepsy Treatment Market Size by Application (2017-2022)
6.3.2 North America Catalepsy Treatment Market Size by Application (2023-2028)
6.3.3 North America Catalepsy Treatment Market Share by Application (2017-2028)
6.4 North America Catalepsy Treatment Market Size by Country
6.4.1 North America Catalepsy Treatment Market Size by Country (2017-2022)
6.4.2 North America Catalepsy Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Catalepsy Treatment Market Size (2017-2028)
7.2 Europe Catalepsy Treatment Market Size by Type
7.2.1 Europe Catalepsy Treatment Market Size by Type (2017-2022)
7.2.2 Europe Catalepsy Treatment Market Size by Type (2023-2028)
7.2.3 Europe Catalepsy Treatment Market Share by Type (2017-2028)
7.3 Europe Catalepsy Treatment Market Size by Application
7.3.1 Europe Catalepsy Treatment Market Size by Application (2017-2022)
7.3.2 Europe Catalepsy Treatment Market Size by Application (2023-2028)
7.3.3 Europe Catalepsy Treatment Market Share by Application (2017-2028)
7.4 Europe Catalepsy Treatment Market Size by Country
7.4.1 Europe Catalepsy Treatment Market Size by Country (2017-2022)
7.4.2 Europe Catalepsy Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Catalepsy Treatment Market Size (2017-2028)
8.2 Asia-Pacific Catalepsy Treatment Market Size by Type
8.2.1 Asia-Pacific Catalepsy Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Catalepsy Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Catalepsy Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Catalepsy Treatment Market Size by Application
8.3.1 Asia-Pacific Catalepsy Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Catalepsy Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Catalepsy Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Catalepsy Treatment Market Size by Region
8.4.1 Asia-Pacific Catalepsy Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Catalepsy Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Catalepsy Treatment Market Size (2017-2028)
9.2 Latin America Catalepsy Treatment Market Size by Type
9.2.1 Latin America Catalepsy Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Catalepsy Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Catalepsy Treatment Market Share by Type (2017-2028)
9.3 Latin America Catalepsy Treatment Market Size by Application
9.3.1 Latin America Catalepsy Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Catalepsy Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Catalepsy Treatment Market Share by Application (2017-2028)
9.4 Latin America Catalepsy Treatment Market Size by Country
9.4.1 Latin America Catalepsy Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Catalepsy Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Catalepsy Treatment Market Size (2017-2028)
10.2 Middle East & Africa Catalepsy Treatment Market Size by Type
10.2.1 Middle East & Africa Catalepsy Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Catalepsy Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Catalepsy Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Catalepsy Treatment Market Size by Application
10.3.1 Middle East & Africa Catalepsy Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Catalepsy Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Catalepsy Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Catalepsy Treatment Market Size by Country
10.4.1 Middle East & Africa Catalepsy Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Catalepsy Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Teva Pharmaceutical Industries
11.1.1 Teva Pharmaceutical Industries Company Details
11.1.2 Teva Pharmaceutical Industries Business Overview
11.1.3 Teva Pharmaceutical Industries Catalepsy Treatment Introduction
11.1.4 Teva Pharmaceutical Industries Revenue in Catalepsy Treatment Business (2017-2022)
11.1.5 Teva Pharmaceutical Industries Recent Developments
11.2 Upsher-Smith Laboratories
11.2.1 Upsher-Smith Laboratories Company Details
11.2.2 Upsher-Smith Laboratories Business Overview
11.2.3 Upsher-Smith Laboratories Catalepsy Treatment Introduction
11.2.4 Upsher-Smith Laboratories Revenue in Catalepsy Treatment Business (2017-2022)
11.2.5 Upsher-Smith Laboratories Recent Developments
11.3 Piramal Critical Care
11.3.1 Piramal Critical Care Company Details
11.3.2 Piramal Critical Care Business Overview
11.3.3 Piramal Critical Care Catalepsy Treatment Introduction
11.3.4 Piramal Critical Care Revenue in Catalepsy Treatment Business (2017-2022)
11.3.5 Piramal Critical Care Recent Developments
11.4 Vintage Labs
11.4.1 Vintage Labs Company Details
11.4.2 Vintage Labs Business Overview
11.4.3 Vintage Labs Catalepsy Treatment Introduction
11.4.4 Vintage Labs Revenue in Catalepsy Treatment Business (2017-2022)
11.4.5 Vintage Labs Recent Developments
11.5 Saol Therapeutics
11.5.1 Saol Therapeutics Company Details
11.5.2 Saol Therapeutics Business Overview
11.5.3 Saol Therapeutics Catalepsy Treatment Introduction
11.5.4 Saol Therapeutics Revenue in Catalepsy Treatment Business (2017-2022)
11.5.5 Saol Therapeutics Recent Developments
11.6 Auxilium Pharmaceuticals
11.6.1 Auxilium Pharmaceuticals Company Details
11.6.2 Auxilium Pharmaceuticals Business Overview
11.6.3 Auxilium Pharmaceuticals Catalepsy Treatment Introduction
11.6.4 Auxilium Pharmaceuticals Revenue in Catalepsy Treatment Business (2017-2022)
11.6.5 Auxilium Pharmaceuticals Recent Developments
11.7 Hikma Pharmaceuticals
11.7.1 Hikma Pharmaceuticals Company Details
11.7.2 Hikma Pharmaceuticals Business Overview
11.7.3 Hikma Pharmaceuticals Catalepsy Treatment Introduction
11.7.4 Hikma Pharmaceuticals Revenue in Catalepsy Treatment Business (2017-2022)
11.7.5 Hikma Pharmaceuticals Recent Developments
11.8 Cadila Pharmaceuticals
11.8.1 Cadila Pharmaceuticals Company Details
11.8.2 Cadila Pharmaceuticals Business Overview
11.8.3 Cadila Pharmaceuticals Catalepsy Treatment Introduction
11.8.4 Cadila Pharmaceuticals Revenue in Catalepsy Treatment Business (2017-2022)
11.8.5 Cadila Pharmaceuticals Recent Developments
11.9 CASI Pharmaceuticals
11.9.1 CASI Pharmaceuticals Company Details
11.9.2 CASI Pharmaceuticals Business Overview
11.9.3 CASI Pharmaceuticals Catalepsy Treatment Introduction
11.9.4 CASI Pharmaceuticals Revenue in Catalepsy Treatment Business (2017-2022)
11.9.5 CASI Pharmaceuticals Recent Developments
11.10 Covis Pharma
11.10.1 Covis Pharma Company Details
11.10.2 Covis Pharma Business Overview
11.10.3 Covis Pharma Catalepsy Treatment Introduction
11.10.4 Covis Pharma Revenue in Catalepsy Treatment Business (2017-2022)
11.10.5 Covis Pharma Recent Developments
11.11 Sumitomo Dainippon Pharma
11.11.1 Sumitomo Dainippon Pharma Company Details
11.11.2 Sumitomo Dainippon Pharma Business Overview
11.11.3 Sumitomo Dainippon Pharma Catalepsy Treatment Introduction
11.11.4 Sumitomo Dainippon Pharma Revenue in Catalepsy Treatment Business (2017-2022)
11.11.5 Sumitomo Dainippon Pharma Recent Developments
11.12 Biocon
11.12.1 Biocon Company Details
11.12.2 Biocon Business Overview
11.12.3 Biocon Catalepsy Treatment Introduction
11.12.4 Biocon Revenue in Catalepsy Treatment Business (2017-2022)
11.12.5 Biocon Recent Developments
11.13 Merck KGaA
11.13.1 Merck KGaA Company Details
11.13.2 Merck KGaA Business Overview
11.13.3 Merck KGaA Catalepsy Treatment Introduction
11.13.4 Merck KGaA Revenue in Catalepsy Treatment Business (2017-2022)
11.13.5 Merck KGaA Recent Developments
11.14 Cadila Pharmaceuticals
11.14.1 Cadila Pharmaceuticals Company Details
11.14.2 Cadila Pharmaceuticals Business Overview
11.14.3 Cadila Pharmaceuticals Catalepsy Treatment Introduction
11.14.4 Cadila Pharmaceuticals Revenue in Catalepsy Treatment Business (2017-2022)
11.14.5 Cadila Pharmaceuticals Recent Developments
11.15 Eisai
11.15.1 Eisai Company Details
11.15.2 Eisai Business Overview
11.15.3 Eisai Catalepsy Treatment Introduction
11.15.4 Eisai Revenue in Catalepsy Treatment Business (2017-2022)
11.15.5 Eisai Recent Developments
11.16 Cipla
11.16.1 Cipla Company Details
11.16.2 Cipla Business Overview
11.16.3 Cipla Catalepsy Treatment Introduction
11.16.4 Cipla Revenue in Catalepsy Treatment Business (2017-2022)
11.16.5 Cipla Recent Developments
11.17 Glenmark Pharmaceuticals Limited
11.17.1 Glenmark Pharmaceuticals Limited Company Details
11.17.2 Glenmark Pharmaceuticals Limited Business Overview
11.17.3 Glenmark Pharmaceuticals Limited Catalepsy Treatment Introduction
11.17.4 Glenmark Pharmaceuticals Limited Revenue in Catalepsy Treatment Business (2017-2022)
11.17.5 Glenmark Pharmaceuticals Limited Recent Developments
11.18 Mankind Pharma
11.18.1 Mankind Pharma Company Details
11.18.2 Mankind Pharma Business Overview
11.18.3 Mankind Pharma Catalepsy Treatment Introduction
11.18.4 Mankind Pharma Revenue in Catalepsy Treatment Business (2017-2022)
11.18.5 Mankind Pharma Recent Developments
11.19 Novo Nordisk A/S
11.19.1 Novo Nordisk A/S Company Details
11.19.2 Novo Nordisk A/S Business Overview
11.19.3 Novo Nordisk A/S Catalepsy Treatment Introduction
11.19.4 Novo Nordisk A/S Revenue in Catalepsy Treatment Business (2017-2022)
11.19.5 Novo Nordisk A/S Recent Developments
11.20 Otsuka America Pharmaceutical
11.20.1 Otsuka America Pharmaceutical Company Details
11.20.2 Otsuka America Pharmaceutical Business Overview
11.20.3 Otsuka America Pharmaceutical Catalepsy Treatment Introduction
11.20.4 Otsuka America Pharmaceutical Revenue in Catalepsy Treatment Business (2017-2022)
11.20.5 Otsuka America Pharmaceutical Recent Developments
11.21 WOCKHARDT
11.21.1 WOCKHARDT Company Details
11.21.2 WOCKHARDT Business Overview
11.21.3 WOCKHARDT Catalepsy Treatment Introduction
11.21.4 WOCKHARDT Revenue in Catalepsy Treatment Business (2017-2022)
11.21.5 WOCKHARDT Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer